Adagio Therapeutics Announces Corporate Name Change to Invivyd
12 September 2022 - 1:00PM
Adagio Therapeutics, (Nasdaq: ADGI), a clinical-stage
biopharmaceutical company on a mission to protect humanity from
serious viral respiratory diseases, announced today that the
Company has changed its name to Invivyd. This new name reflects the
Company’s strategy for leveraging its integrated discovery platform
to develop and commercialize antibodies that transcend the limits
of the human immune system to better prevent and treat infectious
respiratory viral diseases, beginning with COVID-19. In conjunction
with the name change, the Company will begin trading under the new
ticker symbol "IVVD" on the Nasdaq Global Market at market open on
September 13, 2022.
“I’m excited for our new name as it reflects our commitment to
advancing antibody solutions to overcome limitations in both the
immune system and existing COVID-19 treatments,” said David Hering,
Invivyd’s chief executive officer. “Our team understands how
viruses are constantly evolving to exploit the limitations of the
human immune system. Invivyd leverages a platform we believe is
nimble enough to target a virus that will continue to change, and
durable enough to increase the probability of providing a longer
period of protection than other antibody solutions. Our goal is to
change the paradigm for combatting viral infection by delivering
rapid and lasting antibody immunity to protect the general
public and ensure vulnerable populations are never left
behind.”
Invivyd (pronounced “in-viv-id”) has best-in-class antibody
discovery and development capabilities working at the intersection
of evolutionary virology, predictive modeling, and antibody
engineering. The company’s discovery platform is designed with the
aim of providing better solutions to protect the vulnerable with
antibodies engineered to be superior to naturally occurring human
antibodies.
"Now, three years into the human experience with SARS-CoV-2, it
is more clear than ever that we need more durable, more effective
prevention and treatment than can be achieved through the human
immune response,” said Laura Walker, Ph.D., co-founder and chief
scientific officer of Invivyd. “Invivyd has a powerful,
best-in-class integrated discovery platform aimed at identifying
and developing high quality molecules as viral evolution demands. I
am thrilled with the opportunity to deploy our considerable
expertise and resources toward providing ongoing protection to
people in need.”
Beyond COVID-19 the company has multiple antibody candidates in
discovery stage for prevention of seasonal influenza.
Marc Elia, chairman of the Invivyd Board of Directors commented,
"Viral respiratory diseases, including COVID-19, present unique
challenges and impose an unacceptable burden on humankind. We are
delighted to launch an enhanced corporate identity following a
period of change that positions Invivyd to create a meaningful
impact for the company’s stakeholders using its best-in-class
integrated discovery platform and internal capabilities.”
Along with the new name, the Company has adopted a new logo and
refreshed its corporate website to reflect the company’s strategy
moving forward. Visit www.invivyd.com to learn more.
About Invivyd(Nasdaq: IVVD)
Invivyd, formerly Adagio Therapeutics (Nasdaq: ADGI), is a
biopharmaceutical company on a mission to protect humanity from
serious viral respiratory diseases. The company is developing
antibodies to transcend the limits of naturally occurring immunity
and provide superior protection from viral diseases, beginning
with COVID-19. Invivyd’s technology works at the intersection
of evolutionary virology, predictive modeling, and
antibody engineering, and is designed to identify
high-quality, long-lasting antibodies with a high barrier to viral
escape. The company is generating a robust pipeline of products
for use in both prevention and treatment of disease. Invivyd’s most
advanced pipeline candidate is adintrevimab, an investigational
monoclonal antibody which has demonstrated clinically meaningful
results in global Phase 3 clinical trials against multiple variants
of concern for the prevention and treatment of COVID-19.
Adintrevimab is not approved for use in any country. The safety and
efficacy of adintrevimab have not been established. The company
also has multiple discovery stage candidates for the prevention of
seasonal influenza. Visit www.invivyd.com to learn more.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “could,” “expects,”
“intends,” “potential,” “projects,” and “future” or similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements
include statements concerning, among other things, the future of
the COVID-19 landscape including the expectation of continued
evolution and emergence of new variants and subvariants; our
ongoing research and clinical development plans and the timing
thereof; our plans to advance adintrevimab or other early stage
candidates as a potential prophylaxis and treatment option for
COVID-19, including disease caused by most variants, as either a
single or combination agent; the potential for adintrevimab to
demonstrate activity against predominant SARS-CoV-2 variant(s) in
the U.S. and globally; our plans, technology and resources to
develop therapeutic or preventative options for other infectious
diseases, such as additional coronaviruses and seasonal influenza,
in the U.S. and globally; and other statements that are not
historical fact. We may not actually achieve the plans, intentions
or expectations disclosed in our forward-looking statements and you
should not place undue reliance on our forward-looking statements.
These forward-looking statements involve risks and uncertainties
that could cause our actual results to differ materially from the
results described in or implied by the forward-looking statements,
including, without limitation: the impacts of the COVID-19 pandemic
on our business and those of our collaborators, our clinical trials
and our financial position; unexpected safety or efficacy data
observed during preclinical studies or clinical trials; the
predictability of clinical success of adintrevimab or other
pipeline candidates or combination of candidates based on
neutralizing activity in pre-clinical studies; variability of
results in models used to predict activity against SARS-CoV-2
variants of concern; clinical trial site activation or enrollment
rates that are lower than expected; changes in expected or existing
competition; changes in the regulatory environment; the
uncertainties and timing of the regulatory approval process,
including the outcome of our discussions with regulatory
authorities concerning our clinical trials; whether adintrevimab or
any other pipeline candidate or combination of candidates is able
to demonstrate activity against predominant SARS-CoV-2 variant(s)
in the U.S. and globally; whether we are able to successfully
submit an emergency use authorization in the future, and the
outcome of any such emergency use authorization submission; whether
research and development efforts will improve efficacy of
adintrevimab against predominant variants or identify additional
monoclonal antibodies or combination of antibodies for the
prevention and treatment of COVID-19 and other infectious diseases;
whether research and development efforts will identify and result
in safe and effective therapeutic or preventative options for other
infectious diseases in the U.S. or globally and whether we have
adequate funding to meet future operating expenses and capital
expenditure requirements. Other factors that may cause our actual
results to differ materially from those expressed or implied in the
forward-looking statements in this press release are described
under the heading “Risk Factors” in our Annual Report on Form 10-K
for the year ended December 31, 2021 and our Quarterly Report on
Form 10-Q for the quarter ended June 30, 2022, each filed with the
Securities and Exchange Commission (the “SEC”), and in our other
filings with the SEC, and in Invivyd’s future reports to be filed
with the SEC and available at www.sec.gov. Such risks may be
amplified by the impacts of the COVID-19 pandemic. Forward-looking
statements contained in this press release are made as of this
date, and Invivyd undertakes no duty to update such information
whether as a result of new information, future events or otherwise,
except as required under applicable law.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference in this press
release.
Contacts
Media Contact:Tony Berry, Evoke
Canale774-317-0422anthony.berry@evokegroup.com
Investor Contact:Chris Brinzey, ICR
Westwicke339-970-2843chris.brinzey@westwicke.com
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024